Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus FOLFIRI as second-line treatment in advanced colorectal cancer
ChiCTR-OIN-17011000Phase 2Recruiting
- Sponsor
- Cancer Hospital of General Hospital of Ningxia Medical University
- Start
- Apr 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in colorectal cancer (CRC), sponsored by Cancer Hospital of General Hospital of Ningxia Medical University. Primary endpoint: Objective response rate. Started Apr 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-OIN-17011000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17011000.